Prevalence, Symptoms, and Associated Factors of Long COVID-19: A Cross-Sectional Survey Study Long COVID-19 Conditions and Symptoms
Article Sidebar
Main Article Content
Abstract
OBJECTIVE: Long COVID is defined as persistent or newly developed symptoms after the acute phase of COVID-19 infection. This study aimed to evaluate the prevalence of long COVID, types of symptoms, and associated factors.
METHODS: This was a cross-sectional survey including individuals with a history of COVID-19 infection aged ≥ 18 years who were followed up at our hospital. The presence of abnormal symptoms and clinical features were obtained through a questionnaire.
RESULTS: A total of 307 individuals with a median age of 58 years (interquartile range 35–74 years) were included in this study. Among them, 53.1% were females, and 56.0% had underlying diseases. The prevalence of long COVID was 40.1%. Cardiopulmonary (36.6%) and nonspecific general symptoms (22.0%) were the most common symptoms. We did not find significant association long COVID and any characteristic features of the participants, numbers of COVID vaccination or infection episodes.
CONCLUSION: The prevalence of long COVID was 40.1%. No factors significantly associated with long COVID were observed. Cardiopulmonary and general symptoms were the most common symptoms.
Downloads
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
References
World Health Organization. WHO coronavirus disease (COVID-19) dashboard [internet]. [cited 2022 May 10]. Available from: https://covid19.who.int/249
Centers for Disease Control and Prevention. Interim clinical considerations for use of COVID-19 vaccines in the United States [Internet]. 2024 [cited 2025 Apr 28]. Available from: https://www.cdc.gov/vaccines/covid-19/clinical considerations/interim-considerations-us.html
Liu B, Gidding H, Stepien S, Cretikos M, Macartney K. Relative effectiveness of COVID-19 vaccination with 3 compared to 2 doses against SARS-CoV-2 B.1.1.529 (Omicron) among an Australian population with low prior rates of SARS-CoV-2 infection. Vaccine 2022;40(43):6288-94. DOI: https://doi.org/10.1016/j.vaccine.2022.09.029
Petrelli F, Luciani A, Borgonovo K, Ghilardi M, Parati MC, Petrò D, et al. Third dose of SARS-CoV-2 vaccine: A systematic review of 30 publishe d studies. J Me d Virol 2022;94(6):2837-44. DOI: https://doi.org/10.1002/jmv.27644
World Health Organization. Post COVID-19 condition (long COVID) [internet]. 2025 [cited 2025 Apr 28]. Available from: https://www.who.int/news-room/fact-sheets/detail/post-covid-19-condition-(long-covid)
Centers for disease control and prevention. Symptoms of COVID-19 [internet]. [cited 2022 May 12]. Available from: https://www.cdc.gov/coronavirus/2019-ncov/symptoms-testing/symptoms.html
World Health Organization. Post COVID-19 condition (long COVID) [internet]. 2022 [cited 2022 Dec 7]. Available from: https://www.who.int/europe/news-room/fact-sheets/item/post-covid-19-condition
Soriano JB, Murthy S, Marshall JC, Relan P, Diaz JV. A clinical case definition of post-COVID-19 condition by a Delphi consensus. Lancet Infect Dis 2022;22(4):e102-7. DOI: https://doi.org/10.1016/S1473-3099(21)00703-9
Centers for Disease Control and Prevention. Long COVID or post-COVID conditions [internet]. 2022 [cited 2022 May 10]. Available from: https://www.cdc.gov/coronavirus/2019-ncov/long-term-effects/index.html
Wong MC, Huang J, Wong Y, Wong GL, Yip TC, Chan RN, et al. Epidemiology, symptomatology, and risk factors for long COVID symptoms: population-based, multicenter study. JMIR Public Health Surveill 2023;9:e42315. DOI: https://doi.org/10.2196/42315
Jang M, Choi D, Choi J, Kwon HJ. Clinical features and risk factors of post-COVID-19 condition in Korea. J Prev Med Public Health 2023;56(5):431-9. DOI: https://doi.org/10.3961/jpmph.23.124
Chelly S, Rouis S, Ezzi O, Ammar A, Fitouri S, Soua A, et al. Symptoms and risk factors for long COVID in Tunisian population. BMC Health Serv Res 2023;23(1):487. DOI: https://doi.org/10.1186/s12913-023-09463-y
Cazé AB, Cerqueira-Silva T, Bomfim AP, de Souza GL, Azevedo AC, Brasil MQ, et al. Prevalence and risk factors for long COVID after mild disease: a cohort study with a symptomatic control group. J Glob Health 2023;13:06015. DOI: https://doi.org/10.7189/jogh.13.06015
Subramanian A, Nirantharakumar K, Hughes S, Myles P, Williams T, Gokhale KM, et al. Symptoms and risk factors for long COVID in non-hospitalized adults. Nat Med 2022;28(8):1706-14. DOI: https://doi.org/10.1038/s41591-022-01909-w
Phu DH, Maneerattanasak S, Shohaimi S, Trang LTT, Nam TT, Kuning M, et al. Prevalence and factors associated with long COVID and mental health status among recovered COVID-19 patients in southern Thailand. PLoS One 2023;18(7):e0289382. DOI: https://doi.org/10.1371/journal.pone.0289382
Debski M, Tsampasian V, Haney S, Blakely K, Weston S, Ntatsaki E, et al. Post-COVID-19 syndrome risk factors and further use of health services in East England. PLOS Glob Public Health 2022;2(11):e0001188. DOI: https://doi.org/10.1371/journal.pgph.0001188
Somboonviboon D, Aramareerak P, Lertamornpong A, Piyavechviratana K, Pirompanich P. Persistent COVID-19 symptoms and associated factors in a tertiary hospital in Thailand. J Infect Dev Ctries 2024;18(12.1):S318-25. DOI: https://doi.org/10.3855/jidc.19332
Lopez-Leon S, Wegman-Ostrosky T, Perelman C, Sepulveda R, Rebolledo PA, Cuapio A, et al. More than 50 long-term effects of COVID-19: a systematic review and meta-analysis. Preprint. medRxiv [preprint] 2021;2021.01.27.21250617. DOI: https://doi.org/10.21203/rs.3.rs-266574/v1
Nasserie T, Hittle M, Goodman SN. Assessment of the frequency and variety of persistent symptoms among patients with COVID-19: a systematic review. JAMA Netw Open 2021;4(5):e2111417. DOI: https://doi.org/10.1001/jamanetworkopen.2021.11417
Maglietta G, Diodati F, Puntoni M, Lazzarelli S, Marcomini B, Patrizi L, et al. Prognostic factors for post-COVID-19 syndrome: a systematic review and meta-analysis. J Clin Med 2022;11(6):1541. DOI: https://doi.org/10.3390/jcm11061541
O’Mahoney LL, Routen A, Gillies C, Ekezie W, Welford A, Zhang A, et al. The prevalence and long-term health effects of long Covid among hospitalised and non-hospitalised populations: a systematic review and meta-analysis. EClinicalMedicine 2022;55:101762. DOI: https://doi.org/10.1016/j.eclinm.2022.101762
Notarte KI, Catahay JA, Velasco JV, Pastrana A, Ver AT, Pangilinan FC, et al. Impact of COVID-19 vaccination on the risk of developing long-COVID and on existing long-COVID symptoms: a systematic review. EClinicalMedicine 2022;53:101624. DOI: https://doi.org/10.1016/j.eclinm.2022.101624
Woodrow M, Carey C, Ziauddeen N, Thomas R, Akrami A, Lutje V, et al. Systematic review of the prevalence of long COVID. Open Forum Infect Dis 2023;10(7):ofad233. DOI: https://doi.org/10.1093/ofid/ofad233
Tsampasian V, Elghazaly H, Chattopadhyay R, Debski M, Naing TKP, Garg P, et al. Risk factors associated with post-COVID-19 condition: a systematic review and meta-analysis. JAMA Intern Med 2023;183(6):566-80. DOI: https://doi.org/10.1001/jamainternmed.2023.0750
Frallonardo L, Segala FV, Chhaganlal KD, Yelshazly M, Novara R, Cotugno S, et al. Incidence and burden of long COVID in Africa: a systematic review and meta-analysis. Sci Rep 2023;13(1):21482. DOI: https://doi.org/10.1038/s41598-023-48258-3
Daitch V, Yelin D, Awwad M, Guaraldi G, Milić J, Mussini C, et al. Characteristics of long-COVID among older adults: a cross-sectional study. Int J Infect Dis 2022;125:287-93. DOI: https://doi.org/10.1016/j.ijid.2022.09.035
Jindahra P, Wongboonsin K, Wongboonsin P. Demographic and initial outbreak patterns of COVID-19 in Thailand. J Popul Res (Canberra) 2022;39(4):567-88. DOI: https://doi.org/10.1007/s12546-021-09276-y
Cochran WG. Sampling techniques. 3rd ed. New York: John Wiley & Sons; 1977.
Jacobsen PA, Andersen MP, Gislason G, Phelps M, Butt JH, Køber L, et al. Return to work after COVID-19 infection - a danish nationwide registry study. Public Health 2022;203:116-22. DOI: https://doi.org/10.1016/j.puhe.2021.12.012
World Health Organization. A healthy lifestyle – WHO recommendations [internet]. 2010 [cited 2025 Apr 28]. Available from: https://www.who.int/europe/news-room/fact-sheets/item/a-healthy-lifestyle---who-recommendations
Notarte KI, de Oliveira MHS, Peligro PJ, Velasco JV, Macaranas I, Ver AT, et al. Age, sex and previous comorbidities as risk factors not associated with SARS-CoV-2 infection for long COVID-19: a systematic review and meta-analysis. J Clin Med 2022;11(24):7314. DOI: https://doi.org/10.3390/jcm11247314
Bowe B, Xie Y, Al-Aly Z. Acute and postacute sequelae associated with SARS-CoV-2 reinfection. Nat Med 2022;28(11):2398-405. DOI: https://doi.org/10.1038/s41591-022-02051-3
Davis HE, McCorkell L, Vogel JM, Topol EJ. Long COVID: major findings, mechanisms and recommendations. Nat Rev Microbiol 2023;21(3):133-46. DOI: https://doi.org/10.1038/s41579-022-00846-2
Zeng F, Dai C, Cai P, Wang J, Xu L, Li J, et al. A comparison study of SARS-CoV-2 IgG antibody between male and female COVID-19 patients: a possible reason underlying different outcome between sex. J Med Virol 2020;92(10):2050-4. DOI: https://doi.org/10.1002/jmv.25989
Mohamed MS, Moulin TC, Schiöth HB. Sex differences in COVID-19: the role of androgens in disease severity and progression. Endocrine 2021;71(1):3-8. DOI: https://doi.org/10.1007/s12020-020-02536-6
Barek MA, Aziz MA, Islam MS. Impact of age, sex, comorbidities and clinical symptoms on the severity of COVID-19 cases: a meta-analysis with 55 studies and 10014 cases. Heliyon 2020;6(12):e05684. DOI: https://doi.org/10.1016/j.heliyon.2020.e05684
Yasmin F, Najeeb H, Naeem U, Moeed A, Atif AR, Asghar MS, et al. Adverse events following COVID-19 mRNA vaccines: a systematic review of cardiovascular complication, thrombosis, and thrombocytopenia. Immun Inflamm Dis 2023;11(3):e807. DOI: https://doi.org/10.1002/iid3.807
Dixon AE, Peters U. The effect of obesity on lung function. Expert Rev Respir Med 2018;12(9):755-67. DOI: https://doi.org/10.1080/17476348.2018.1506331
